References
- Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 125(1), e2–e220 (2012).
- Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297(2), 177–186 (2007).
- Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326(7404), 1419 (2003).
- Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N. Engl. J. Med. 327(4), 248–254 (1992).
- Gottlieb SS, McCarter RJ, Vogel RA. Effect of β-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N. Engl. J. Med. 339(8), 489–497 (1998).
- Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ 318(7200), 1730–1737 (1999).
- Simpson CR, Buckley BS, McLernon DJ, Sheikh A, Murphy A, Hannaford PC. Five-year prognosis in an incident cohort of people presenting with acute myocardial infarction. PLoS ONE 6(10), e26573 (2011).
- Konishi M, Haraguchi G, Yoshikawa S, Kimura S, Inagaki H, Isobe M. Additive effects of β-blockers on renin–angiotensin system inhibitors for patients after acute myocardial infarction treated with primary coronary revascularization. Circ. J. 75(8), 1982–1991 (2011).
- Zuckerman IH, Yin X, Rattinger GB et al. Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults. J. Am. Geriatr. Soc. 60(10), 1854–1861 (2012).
- Kezerashvili A, Marzo K, De Leon J. β-blocker use after acute myocardial infarction in the patient with normal systolic function: when is it ‘ok’ to discontinue? Curr. Cardiol. Rev. 8(1), 77–84 (2012).
- Klapholz M. β-blocker use for the stages of heart failure. Mayo Clin. Proc. 84(8), 718–729 (2009).
- McLean RC, Hirsch GA, Becker LC, Kasch-Semenza L, Gerstenblith G, Schulman SP. Polymorphisms of the β adrenergic receptor predict left ventricular remodeling following acute myocardial infarction. Cardiovasc. Drugs Ther. 25(3), 251–258 (2011).
- Cresci S, Dorn GW 2nd, Jones PG et al. Adrenergic-pathway gene variants influence β-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J. Am. Coll. Cardiol. 60(10), 898–907 (2012).
- Bramlage P, Messer C, Bitterlich N et al. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 96(8), 604–609 (2010).
- Ho PM, Spertus JA, Masoudi FA et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch. Intern. Med. 166(17), 1842–1847 (2006).
- Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J. Gen. Intern. Med. 23(2), 115–121 (2008).
- Phillips KA, Shlipak MG, Coxson P et al. Health and economic benefits of increased β-blocker use following myocardial infarction. JAMA 284(21), 2748–2754 (2000).
- Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost–effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 117(10), 1261–1268 (2008).